Source: Annual Congress 2011 - Lung development and neoplasia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Leppäranta, M. Bespalov, M. Myllärniemi, K. Koli (Helsinki, Finland). Molecular screening – A search for potential drugs for idiopathic pulmonary fibrosis. Eur Respir J 2011; 38: Suppl. 55, 3806

Member's Comments

No comment yet.

Related content which might interest you: Clinical analysis of chronic hypersensitivity pneunonitis – Comparison with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease Year: 2010 Pulmonary rehabilitation in patients with interstitial lung disease – An useful therapeutic option? Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 LATE-BREAKING ABSTRACT: Inhibition of MAP3K19 - A novel therapeutic approach for treatment of IPF Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Identifying pulmonary hypertension in patients with interstitial lung disease – Evaluating an unmet need Source: Annual Congress 2010 - Pulmonary circulation III Year: 2010 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future}, Source: Eur Respir Rev 2013; 22: 281-291 Year: 2013 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Idiopathic pulmonary fibrosis: approaches to diagnostic Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002 Tolerance of pirfenidone in Indian patients with idiopathic pulmonary fibrosis – Usual interstial pneumonitis: An initial experience Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Idiopathic pulmonary fibrosis (IPF): epidemiology, biology, diagnosis and treatment Source: Virtual Congress 2020 – When the lung gets stiff Year: 2020 Surgical lung biopsy – Gold standard for diagnosis of idiopathic interstitial pneumonia? Source: Annual Congress 2012 - New insights in the clinical management of lung diseases Year: 2012 Late Breaking Abstract: Pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF) in early course of disease – A prospective evaluation with right heart catheterization (RHC) in the ARTEMIS-IPF study Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019 Year: 2019 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 Chronic post-embolic pulmonary hypertension: a new target for medical therapies?}, Source: Eur Respir Rev 2013; 22: 258-264 Year: 2013